US regulatory status: approved. Molecular target: L-lactate dehydrogenase A chain mRNA.
- Target
- L-lactate dehydrogenase A chain mRNA
- Mechanism
- L-lactate dehydrogenase A chain mRNA RNAi inhibitor
pharma · Fertility · INTI
Inhibitor Therapeutics
Inhibitor Therapeutics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Tampa, USA HQ
2013 Founded
5 Employees
Public company Type
INTI · NYSE Ticker
Company details
- Status
- Public
- HQ
- Tampa, USA
- Founded
- 2013
- Employees
- 5
- Programs
- 2
- Drugs
- 2
- Patents
- 5
Inhibitor Therapeutics pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Inhibitor Therapeutics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
smallpox and monkeypox vaccine (live modified vaccinia virus ankara)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Inhibitor Therapeutics's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response